Dr. Singh Discusses the Future of Immunotherapy in GIST – OncLive
OncLive |
Dr. Singh Discusses the Future of Immunotherapy in GIST
OncLive In a trial of nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy), patients with heavily pretreated GIST demonstrated encouraging responses to the combination of immunotherapy. Interim data from the first 14 patients was presented at … |
